You are here

A Study Of PF-05190457 In Healthy Volunteers And Type-2 Diabetic Patients

Last updated on May 10, 2018

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
New Haven, Connecticut, 06511 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Type 2 Diabetes Mellitus
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-55 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Healthy males and females of non-childbearing potential between ages of 18 and 55
years, BMI of 18.5 to 30.5 kg/m^2, and weight between 50 and 100 kg, inclusive.

- Type 2 diabetic males and females of non-childbearing potential between ages of 18 and
55 years, BMI of 18.5 to 40.0 kg/m^2, weight between 50 and 150 kg, and HbA1c of
7.0-10.0%, inclusive.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Evidence or history of clinically significant hematological, renal, endocrine,
pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or
allergic disease.

- Additionally, type 2 diabetic patients who have history of diabetic complications with
significant end-organ damage or pharmacologic treatment for diabetes in addition to
metformin.

NCT01372163
Pfizer
Terminated
A Study Of PF-05190457 In Healthy Volunteers And Type-2 Diabetic Patients

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Ovarian Cancer HR+ HER2- Metastatic Breast Cancer
NCT03519178
All Genders
18+
Years
Multiple Sites
Part 1, MELANOMA, SCCHN, OVCA, SARCOMA, OTHER SOLID TUMORS, Part 1 and 2, NSCLC, UROTHELIAL CARCINOMA
NCT02573259
All Genders
18+
Years
Multiple Sites
A Study Of PF-05190457 In Healthy Volunteers And Type-2 Diabetic Patients
A Phase 1 Placebo-Controlled Trial To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Multiple Ascending Doses Of PF-05190457 In Healthy And Type 2 Diabetic Adults
The purpose of the study is to evaluate the safety and tolerability of PF-05190457 after administration of multiple doses to healthy volunteers and Type 2 diabetic patients and to evaluate the plasma drug concentrations after multiple doses.
Not Provided
Interventional
Phase 1
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Basic Science
Diabetes Mellitus, Type 2
  • Drug: PF-05190457 or Placebo
    Twice daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast and dinner in healthy volunteers.
  • Drug: PF-05190457 or Placebo
    Once daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast in healthy volunteers.
  • Drug: PF-05190457 or Placebo
    Once (or twice) daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast (and dinner if twice) in Type 2 Diabetic patients.
  • Experimental: 2 mg PF-05190457 or Placebo BID
    Intervention: Drug: PF-05190457 or Placebo
  • Experimental: 10 mg PF-05190457 or Placebo BID
    Intervention: Drug: PF-05190457 or Placebo
  • Experimental: 40 mg PF-05190457 or Placebo BID
    Dose and dose frequency may be adjusted based on emerging safety and PK data.
    Intervention: Drug: PF-05190457 or Placebo
  • Experimental: 150 mg PF-05190457 or Placebo BID
    Dose and dose frequency may be adjusted based on emerging safety and PK data.
    Intervention: Drug: PF-05190457 or Placebo
  • Experimental: 5 mg PF-05190457 or Placebo QD
    Dose and dose frequency may be adjusted based on emerging safety and PK data.
    Intervention: Drug: PF-05190457 or Placebo
  • Experimental: 50 mg PF-05190457 or Placebo QD
    Dose and dose frequency may be adjusted based on emerging safety and PK data.
    Intervention: Drug: PF-05190457 or Placebo
  • Experimental: xxx mg PF-05190457 or Placebo
    Dose and dose frequency to be determined based on emerging safety and PK data.
    Intervention: Drug: PF-05190457 or Placebo
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
35
April 2012
April 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Healthy males and females of non-childbearing potential between ages of 18 and 55 years, BMI of 18.5 to 30.5 kg/m^2, and weight between 50 and 100 kg, inclusive.
  • Type 2 diabetic males and females of non-childbearing potential between ages of 18 and 55 years, BMI of 18.5 to 40.0 kg/m^2, weight between 50 and 150 kg, and HbA1c of 7.0-10.0%, inclusive.

Exclusion Criteria:

  • Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease.
  • Additionally, type 2 diabetic patients who have history of diabetic complications with significant end-organ damage or pharmacologic treatment for diabetes in addition to metformin.
Sexes Eligible for Study: All
18 Years to 55 Years   (Adult)
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT01372163
B3301002
No
Not Provided
Not Provided
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
May 2012

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

Clinic[email protected]



Call Now